Thomas Glocer - Merck Independent Director
| MRCK34 Stock | BRL 82.00 0.24 0.29% |
Director
Mr. Thomas H. Glocer is Independent Director of the Company.Mr. Glocer has extensive management, operational, technology and international business expertise, including his history of accomplishment and executive ability as CEO and a Director of Thomson Reuters Corporationrationration. In addition, his directorships at other public companies, including his service as Lead Director and as a member of the Operations and Technology Committee at Morgan Stanley, provide him with valuable experience on governance issues facing public companies. He is Retired Chief Executive Officer, Thomson Reuters Corporation since December 2011, prior to which he was Chief Executive Officer of Thomson Reuters from 2008 and Chief Executive Officer of its predecessor, Reuters Group PLC, from 2001. Founder and Managing Partner, Angelic Ventures, L.P Director, Council on Foreign Relations nominated Director, Morgan Stanley Member, Board of Trustees, Cleveland Clinic, European Business Leaders Council, Atlantic Council International Advisory Board, Madison Council of the Library of Congress, The Business Council, Advisory Board of the Cambridge Judge Business School, the Columbia College Board of Visitors, and Presidents Council on International Activities at Yale University since 2007.
| Age | 58 |
| Tenure | 17 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Roos | salesforce inc | 63 | |
| Maynard Webb | salesforce inc | 62 | |
| Fernando Iunes | Metalurgica Gerdau SA | 56 | |
| Neelie Kroes | salesforce inc | 67 | |
| Colin Powell | salesforce inc | 79 | |
| Paulo Bilyk | Metalurgica Gerdau SA | N/A | |
| Aod Moraes | Metalurgica Gerdau SA | N/A | |
| Mary Wilderotter | Costco Wholesale | 62 | |
| Alan Hassenfeld | salesforce inc | 69 | |
| Richard Johannpeter | Metalurgica Gerdau SA | 44 | |
| Luiz Santos | Metalurgica Gerdau SA | N/A | |
| Susan Decker | Costco Wholesale | 55 | |
| Heinz Junker | MAHLE Metal Leve | 65 | |
| Susan Wojcicki | salesforce inc | 48 | |
| Kenneth Denman | Costco Wholesale | 59 | |
| Mauro Arruda | MAHLE Metal Leve | 68 | |
| Bernhard Volkmann | MAHLE Metal Leve | 65 | |
| John Stanton | Costco Wholesale | 62 | |
| Charles Munger | Costco Wholesale | 94 | |
| Parker Harris | salesforce inc | 56 | |
| Jeffrey Raikes | Costco Wholesale | 59 | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| Rochelle Lazarus, Independent Director | ||
| Wendell Weeks, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Paul Rothman, Director | ||
| Mary Coe, Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Joseph Romanelli, IR Contact Officer | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Jennifer Mauer, VP Communications | ||
| Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
| Leslie Brun, Independent Director | ||
| Inge Thulin, Director | ||
| Pamela Craig, Director | ||
| Patricia Russo, Independent Director | ||
| David Williams, Ex Officer | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Lisa LeCointeCephas, VP Officer | ||
| Robert Davis, CFO and Executive VP | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Chief Marketing Officer | ||
| Peter Dannenbaum, VP Relations | ||
| Clark Golestani, CIO and Executive VP | ||
| William Harrison, Lead Independent Director | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Steven Mizell, Chief Human Resource Officer | ||
| Jim Scholefield, Chief Information and Digital Officer | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Frank Clyburn, Chief Commercial Officer | ||
| Robert JD, CEO Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 1.6 T | |||
| Shares Outstanding | 20.28 B | |||
| Price To Earning | 96.57 X | |||
| Price To Book | 6.31 X | |||
| Price To Sales | 25.29 X | |||
| Revenue | 59.28 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Merck information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |